Evidence map›Paper›PMID 36139698›Full record

ArticleCancers2022

RNA-seq and ChIP-seq Identification of Unique and Overlapping Targets of GLI Transcription Factors in Melanoma Cell Lines.

Matea Kurtović, Nikolina Piteša, Nenad Bartoniček, Petar Ozretić, Vesna Musani, Josipa Čonkaš, Tina Petrić, Cecile King, Maja Sabol

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Tumor-derived GLI1 promotes remodeling of the immune tumor microenvironment in melanoma.Journal of experimental & clinical cancer research : CR · 2024
    Article
  4. Article
  5. Inflammation and tumor microenvironment.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Matea KurtovićDivision of Molecular Medicine, Ruđer Bošković Institute, 10 000 Zagreb, Croatia.
Nikolina PitešaDivision of Molecular Medicine, Ruđer Bošković Institute, 10 000 Zagreb, Croatia.
Nenad BartoničekThe Garvan Institute of Medical Research, 384 Victoria St., Darlinghurst, NSW 2010, Australia.
Petar OzretićDivision of Molecular Medicine, Ruđer Bošković Institute, 10 000 Zagreb, Croatia.ORCID 0000-0001-9757-6636
Vesna MusaniDivision of Molecular Medicine, Ruđer Bošković Institute, 10 000 Zagreb, Croatia.ORCID 0000-0001-9927-3727
Josipa ČonkašDivision of Molecular Medicine, Ruđer Bošković Institute, 10 000 Zagreb, Croatia.
Tina PetrićDivision of Molecular Medicine, Ruđer Bošković Institute, 10 000 Zagreb, Croatia.
Cecile KingSchool of Biotechnology and Biomolecular Sciences, Faculty of Science, University of New South Wales, Sydney, NSW 2052, Australia.
Maja SabolDivision of Molecular Medicine, Ruđer Bošković Institute, 10 000 Zagreb, Croatia.ORCID 0000-0001-6968-2327
Ruđer Bošković Institute · HRGarvan Institute of Medical Research · AUUNSW Sydney · AU

Funding

Australian Research Council DP210103811Croatian Science Foundation IP-2018-01-4889National Health and Medical Research Council 2004306
6 · The paper itself

Abstract

backgroundDespite significant progress in therapy, melanoma still has a rising incidence worldwide, and novel treatment strategies are needed. Recently, researchers have recognized the involvement of the Hedgehog-GLI (HH-GLI) signaling pathway in melanoma and its consistent crosstalk with the MAPK pathway. In order to further investigate the link between the two pathways and to find new target genes that could be considered for combination therapy, we set out to find transcriptional targets of all three GLI proteins in melanoma.

methodsWe performed RNA sequencing on three melanoma cell lines (CHL-1, A375, and MEL224) with overexpressed GLI1, GLI2, and GLI3 and combined them with the results of ChIP-sequencing on endogenous GLI1, GLI2, and GLI3 proteins. After combining these results, 21 targets were selected for validation by qPCR.

resultsRNA-seq revealed a total of 808 differentially expressed genes (DEGs) for GLI1, 941 DEGs for GLI2, and 58 DEGs for GLI3. ChIP-seq identified 527 genes that contained GLI1 binding sites in their promoters, 1103 for GLI2 and 553 for GLI3. A total of 15 of these targets were validated in the tested cell lines, 6 of which were detected by both RNA-seq and ChIP-seq.

conclusionsOur study provides insight into the unique and overlapping transcriptional output of the GLI proteins in melanoma. We suggest that our findings could provide new potential targets to consider while designing melanoma-targeted therapy.

Indexed as

GLI targetsHH-GLI pathwayMAPK pathwaymelanomatargeted therapy

Identifiers

PMID36139698
PMCPMC9497141
OpenAlexW4296526222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.